ATLRF Atlas Copco Corporation (PK)

Aethlon Medical, Inc. (OTCBB:AEMD) announced that its Chairman & CEO, James A. Joyce was interviewed by The Wall Street Reporter today. Mr. Joyce discussed Aethlon's strategy for treating biological weapons and described how the Company's Hemopurifier(TM) treatment technology is positioned to be the first line of defense against several drug and vaccine resistant bioweapons. Mr. Joyce also indicated that pre-clinical blood studies have demonstrated the effectiveness of the Hemopurifier in capturing pox viruses related to Smallpox. The interview can be accessed at www.wallstreetreporter.com through Friday, May 6th. About Aethlon Medical Aethlon Medical is pioneering the development of viral filtration devices to treat drug and vaccine resistant pathogens. The market focus is the treatment of the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon candidates. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the infectious disease, biowarfare, and dialysis industries. Clinical Trials to treat HIV and HCV patients in India are scheduled to begin in the coming months, and U.S. clinical studies are expected to begin later this year. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com. Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.